Theratechnologies (TH) Receives a Hold from RBC Capital


The Healthcare company, Theratechnologies (TH), has received a rating update from a Wall Street analyst yesterday. Analyst Brian Abrahams from RBC Capital rated Theratechnologies (TH) a Hold, setting a C$10 price target.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 8.8% and a 50.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Enanta Pharmaceuticals, and Corbus Pharmaceuticals.

Read also: Tilray (TLRY) Ramping up Cannabis Supply in Canada with Acquisition of Natura Naturals Holdings

Currently, the analyst consensus on Theratechnologies is a Hold with an average price target of C$10.10.

The company has a one-year high of C$14.75 and a one-year low of C$6.72. Currently, Theratechnologies has an average volume of 153.1K.

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). It offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

The company’s shares closed on Thursday at C$8.34.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts